North America Bioprocess Technology Market Forecast to 2028 - Regional Analysis By Type, Modality, and End User

The North America bioprocess technology market is expected to grow from US$ 15,869.06 million in 2023 to US$ 33,696.06 million by 2028. It is estimated to grow at a CAGR of 16.3% from 2023 to 2028.

Increasing Prevalence of Chronic Diseases Drives North America Bioprocess Technology Market

The unprecedented rate of aging population and extended periods of physical inactivity are boosting the prevalence lifestyle disorders, such as obesity and diabetes. Genes can cause conditions such as cardiovascular disease (CVDs), diabetes, obesity, Alzheimer's disease, and depression. According to the National Council on Aging, Inc., 80% of adults (aged 65 and more) are reported to suffer from at least one chronic condition in their lifetime, while 68% have two or more. According to the Centers for Disease Control and Prevention (CDC), nearly 6 of 10 people in the US suffered from at least one serious disease, and 4 of 10 people have had two or more chronic conditions in 2020. CVDs, such as angina pectoris, atherosclerosis, and acute myocardial infarction, caused due to hectic lifestyles are significant causes of mortality across the region. Diabetes is a life-threatening chronic disease with no functional cure. Diabetes of all types can cause various complications in different body parts, thereby increasing the overall risk of death. Heart attack, kidney failure, stroke, leg amputation, nerve damage, and vision loss are among the major complications associated with diabetes. According to the International Diabetes Federation (IDF), diabetic cases in North America are expected to reach 62 million by 2045 from 46 million in 2017. The data further reported that 425 million people suffered from diabetes in 2017, and the count is likely to reach 629 million by 2045 worldwide. The disease prevalence is likely to increase by about 35% during the forecast period. Recognition of biosimilars as efficacious and safe agents by patients, specialists, primary care clinicians, and other healthcare professionals is propelling its demand. Biosimilars have proven to improve the quality of life for millions of patients. They are effective and cost-effective options in treating many diseases, including chronic skin conditions (such as psoriasis, Atopic Dermatitis), bowel diseases (such as Crohn’s disease, irritable bowel syndrome, and colitis), diabetes, autoimmune disease, cancer, kidney conditions, and arthritis. Biosimilar developers are adopting advanced bioprocessing technologies to achieve lower manufacturing costs, an important factor determining final consumer prices. Nearly all biosimilar developers are using modern, often cutting-edge bioprocessing techniques. This indicates that a majority of biosimilars are being developed using single use (disposed of after-use) bioprocessing systems. With the growing prevalence of chronic diseases, the demand for biosimilars to treat life-threatening illnesses is spurring, thereby propelling the demand for bioprocessing technologies.

North America Bioprocess Technology Market Overview

According to the Food and Drug Administration (FDA) report, over 30 million people in the US suffer from ~7,000 rare diseases, accounting for life-threatening conditions with low treatment options. Drug, biological, and device development in the treatment of rare diseases is challenging due to a lack of understanding of the history of rare diseases and difficulty in conducting clinical trials. Therefore, the growth of bioprocess technologies such as gene and cell therapies (CGTs) and specialty pharmaceuticals represent a radical shift in the treatment of rare diseases. For example, CGTs have revealed significant health benefits than formulated drugs for treating rare diseases. In the US, more than 900 investigational new drug (IND) applications targeting gene therapy products are underway. Also, 10-20 gene therapies are approved annually by the FDA. Likewise, in August 2022, the FDA approved Bluebird Bio's"Zynteglo (betibeglogene autotemcel)." It was the most expensive single-application drug approval in the US intended for the treatment of a rare neurological disorder-cerebral adrenoleukodystrophy (CALD).
North America Bioprocess Technology Market Revenue and Forecast to 2028 (US$ Million)

North America Bioprocess Technology Market Segmentation

The North America bioprocess technology market is segmented into type, modality, end user, and country.

Based on type, the North America bioprocess technology market is segmented into cell culture media bioprocess, chromatography bioprocess, and consumables & accessories, and others. In 2023, the cell culture media bioprocess segment registered a largest share in the North America bioprocess technology market.

Based on modality, the North America bioprocess technology market is bifurcated into single use and multiple use. In 2023, the single use segment registered a larger share in the North America bioprocess technology market.

Based on end-use, the North America bioprocess technology market is segmented into academic & medical institutions, biopharmaceutical companies, research laboratories, and others. In 2023, the biopharmaceutical companies segment registered a largest share in the North America bioprocess technology market.

Based on country, the North America bioprocess technology market is segmented into the US, Canada, and Mexico. In 2023, the US segment registered a largest share in the North America bioprocess technology market.

Corning Inc; Danaher Corp; Eppendorf SE; Lonza Group AG; Merck KGaA; Repligen Corp; Sartorius AG; STAMM Biotech; and Thermo Fisher Scientific Inc are some of the leading companies operating in the North America bioprocess technology market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America bioprocess technology market.
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the North America bioprocess technology market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth North America market trends and outlook coupled with the factors driving the bioprocess technology market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution